Happiest Minds Technologies Ltd. share price target

We maintain our BUY rating on the stock.

We expect FY27 revenue growth to track the 12.5% YoY revenue growth guidance, supported by accelerating AI adoption, resilient BFSI and Healthcare demand, and a healthy large deal pipeline.

We expect Happiest Minds to report a steady Q1FY27 with USD revenue of USD 66.9 Mn (+2.8% QoQ, +3.9% YoY), driven by the winning of Artha banking license deals (right shifted from Q4FY26) and healthy growth momentum across EdTech and Healthcare verticals.

Happiest Minds Technologies Ltd provides digital transformation and technology services to the automotive, banking, financial services and insurance (BFSI), consumer packaged goods, e-commerce, edtech, engineering research and development, hitech, manufacturing, retail, and travel, transportation and hospitality sectors. The company's consolidated revenue rose 10.9% YoY in Q4FY26 to Rs. 604cr, supported by steady demand across its business segments, with a further...

We believe Happiest Minds Technologies to grow it’s Revenue/EBITDA/PAT at a CAGR of 8.9%/6.7%/13.0% over FY26-FY28E, which translates the stock trading at 16x FY28E. We value the stock at 23x implying a Target Price of 510 (37% Upside).

Given the company's strong growth potential backed by robust deal wins and superior execution capabilities, Happiest Minds is expected to continue reporting healthy growth in the coming quarters. Consequently, we maintain our BUY rating on the stock.

We maintain our BUY rating on the stock.

Happiest Minds is expected to sustain double-digit revenue growth over the next three to four years, supported by steady execution and resilient margins. The Generative AI *over or under performance to benchmark index Business Services (GBS) and Net New (NN) unit continue to scale well, driving strong client additions and deeper artificial intelligence (AI)-led engagements. Growth visibility remains healthy across key verticals, with BFSI poised for recovery and healthcare gaining traction owing to modernisation and AI-driven programmes. Strategic investments in talent, vertical depth and sales capabilities are enhancing scalability and...

Revenue conversion is expected to remain muted in the near term amid an industry-wide slowdown and tight discretionary budgets, leading to extended decision cycles and deal ramp-up delays in select IMSS and BFSI engagements.

Given the company's strong growth potential backed by robust deal wins and superior execution capabilities, it is expected to continue reporting healthy growth in the coming quarters. Consequently, we maintain our BUY rating on the stock.

We recommend a BUY on Happiest Minds Technologies Ltd. with a Target Price of Rs 690/share, offering an upside potential of 23% from the current market price.

The company has shown impressive YoY revenue growth and improving profitability and margin, particularly aided by the BFSI and healthcare sectors. With expectations of double-digit revenue growth and EBITDA margin between 20-22% in the future, the company's prospects are bright. New transformational initiatives and investments in the GenAI business unit are expected to boost profitability. Additionally, the company's strong performance in the BFSI and healthcare segments, driven by new client acquisitions and a healthy pipeline, will likely...

Given the company's strong growth potential backed by robust deal wins and superior execution capabilities, the company is expected to report healthy growth. Hence, we resume our coverage with a BUY rating on the stock.

Happiest Minds (HAPPSTMNDS) reported 25.6% YoY CC growth in FY25, lower than its guidance of 27-28%. Organic growth for FY25 stood at ~3.2% as per our estimate.

Happiest Minds (HAPPSTMNDS) has once again revised down its FY25 revenue target to 27-28% vs 30-35% YoY CC earlier. We cut revenue by 7%/9% for FY26-27E, factoring in lower organic growth momentum and softness in edutech.

Happiest Mind’s (HAPPSTMN) operating performance undershot estimates with both margin and revenue missing their marks.

Given the company's strong growth potential backed by robust deal wins and superior execution capabilities, we recommend a BUY rating on the stock.

Given the company's strong growth potential backed by robust deal wins and superior execution capabilities, we recommend a BUY rating on the stock.